PPARG and asthma: used Bergenin, a PPARγ agonist, to block the differentiation of naive CD4+ T cells into Th17 cells by inhibiting GLS1-dependent glutaminolysis under Th17-polarizing condition, thus alleviating asthma in mouse model (102).